Vernalis Information & Vernalis Links at HealthHaven.com

Vernalis *plc*
(LSE:VER.L Nasdaq:VNLS)
Type	Public
Founded	2003 from merger
Headquarters	Winnersh, United Kingdom
Key people	CEO; Robert Mansfield, 1992-2003; Simon Sturge, 2003-; Chair; George Kennedy, 2000-2003; Peter Fellner, 2003-
Industry	Biotechnology
Products	Frovatriptan, Apokyn
Employees	200
Website	Vernalis

Vernalis Plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.^[1] The merger allowed British Biotech to ditch its historic but tarnished name.^[2]

The company has marketed two drug products; Frovatriptan,,^[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.^[4]

The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono.